logo
Are you taking Ozempic, Wegovy, or other GLP-1 drug for weight loss? Here's what to know about the costs.

Are you taking Ozempic, Wegovy, or other GLP-1 drug for weight loss? Here's what to know about the costs.

Boston Globe30-04-2025

The state's second-largest insurer,
Whether GLP-1s are covered by insurance has huge implications nationally because the drugs, which were first approved to treat diabetes and later obesity, are also being studied for possible future treatment of a
Advertisement
Here's what you should know about GLP-1s and how they're covered.
How much do GLP-1 drugs cost out of pocket?
The monthly price ranges from about $950 to $1,350, which adds up to more than $11,000 a year, at a minimum, before insurance and discounts.
Advertisement
What are the brand names of GLP-1s?
Ozempic and Wegovy are two of the most well-known, due to extensive TV and marketing efforts. Others are Mounjaro, Saxenda, Trulicity, and Zepbound. GLP-1s are currently considered the world's hottest pharmaceutical products.
What does GLP-1 stand for?
Glucagon-like peptide. It is a hormone that plays a crucial role in regulating blood sugar, appetite, and digestion. It works primarily by stimulating insulin release, suppressing glucagon secretion, slowing gastric emptying, and increasing a feeling of fullness after eating.
Will other insurers follow Blue Cross's example by eliminating GLP-1 coverage?
Blue Cross is the dominant and most influential commercial health insurer in the state, with 3 million members. It's hard to imagine that Point32Health, the next largest commercial insurer with 1.5 million members, will continue to compete with Blue Cross at a significant financial disadvantage by covering expensive GLP-1s.
Will my employer help defray the cost if my GLP-1 coverage is ended?
There is a chance your employer will pick up at least some of the cost because doing so may help in employee recruitment and retention. But there is less flexibility for employers to do so if they have fewer than 100 employees and are 'fully insured,' as opposed to 'self-insured.' (Blue Cross and Point32Health offer both types of plans — more on this below.)
How does a fully insured plan work?
Smaller employers often avoid some of the risk of health insurance losses by contracting with an insurer such as Blue Cross to assume the risk of huge, unforeseen spikes in claims. (Those insurers also administer the plan.) When an insurer assumes the risk, it controls all aspects of the plan, including what drugs are — and are not — covered. In these circumstances, an employer has little discretion to add coverage of a drug such as GLP-1s. They must strictly adhere to the plan as designed by their insurer.
How does the size of the company affect insurance?
Because of the popularity of GLP-1s, Blue Cross is allowing more flexibility than usual for fully insured companies. Ordinarily, it would allow no variances in its plans. But for GLP-1s, it is allowing employers to continue to offer coverage of GLP-1s, so long as the companies agree to pay significant increases in premiums. But the option to continue coverage of GLP-1s is not available to companies of 100 or fewer employees because it is deemed too risky to the insurer.
Advertisement
How does a self-insured plan work?
Self-insured employers are bigger companies with more resources that hire an insurer like Blue Cross to administer an insurance plan, but the employer assumes the risk of claims exceeding premiums. Because they pay their own claims, they are free to make changes in the plans they offer, including by adding coverage of GLP-1s (with an increase in premiums paid by employees).
How should I approach my employer about what drugs are covered in my insurance plan?
Insurance coverage is among the most important benefits offered by employers. (More than half of the state's residents are covered by an employer-sponsored health plan.) If you belong to a union, health insurance is a major component of contract negotiations. If you are choosing between job offers, the quality of the offered insurance may be a big factor in your decision. If GLP-1 coverage is important to you, make sure your views are communicated to your employer's decision makers.
Why would an employer opt to cover GLP-1s?
Besides recruitment and retention, a company may see GLP-1s as a path to lower its costs in the long run because weight loss generally improves health and could result in fewer and less expensive claims later. Some see GLP-1s as possibly significantly lowering overall future health costs.
How do I know if my employer is fully insured or self-insured?
Contact your company's HR department or check your health insurance paperwork. On the back of my insurance ID card it says my insurer 'administers claims payments and does not assume financial risk,' meaning my plan is self-insured.
Advertisement
Are GLP-1s covered by Medicare?
Medicare does not cover GLP-1s prescribed solely for weight loss. But it does cover GLP-1s prescribed to reduce the risk of heart attack and stroke due to cardiovascular disease and obesity or being overweight.
President Trump upon taking office reversed the Biden administration's plan to expand Medicare coverage by including GLP-1s for weight loss.
Do Medicare supplemental plans cover GLP-1s?
They usually follow Medicare policies, so, generally, no, GLP-1s are not covered for weight loss.
Are GLP-1s covered by MassHealth?
MassHealth covers Zepbound for treatment for weight loss.
What's the future of the industry?
Drug companies are racing to produce GLP-1s in the form of a daily pill instead of requiring weekly injections, among other potential advances. They are also trying to reduce the side effects of these drugs.
Will the cost of GLP-1s eventually decline?
Yes, prices are expected to drop due to increased competition, generic versions, potential price negotiation in Medicare, and other factors. But increased demand could
Are 'compounded' versions of GLP-1s available?
Compounded drugs are made by pharmacies and are typically allowed by the Food and Drug Administration to augment supply when there's a shortage of the brand-name drug (though they are not FDA-approved). Such a shortage existed for some GPL-1s, but the FDA this month said the shortage has been resolved. The compounded drugs are
Got a problem? Send your consumer issue to

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program

Yahoo

time5 hours ago

  • Yahoo

RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program

BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@

Common Childhood Virus Linked to Alzheimer's Development in Old Age
Common Childhood Virus Linked to Alzheimer's Development in Old Age

Yahoo

time7 hours ago

  • Yahoo

Common Childhood Virus Linked to Alzheimer's Development in Old Age

A study published 30 years ago is striking up new conversation about the potential connection between the common cold sore and Alzheimer's disease. Published in The Lancet in 1997, researchers compared DNA extracted from the brains of elderly people with and without Alzheimer's, and in some of them, found herpes simplex virus 1 (HSV-1)—an infection often contracted in childhood—dormant in the nerves. Ultimately, researchers predicted that those with HSV-1 and a specific gene, called the ApoE-e4 gene, had a higher risk of developing Alzheimer's. Meet the Experts: David Hunter, M.D., an assistant professor and neurologist with UTHealth Houston, Linda Yancey, M.D., an infectious disease doctor at Memorial Hermann Health System; and Mark Santos, Ph.D., an assistant professor of microbiology and immunology at Touro University Nevada. Study co-author Ruth Itzhaki, Ph.D., summarized her team's findings in a recent article for The Conversation and noted that, over the years, additional work has surfaced to support hers. But what does it all mean, exactly? If a cold sore pops up, should you be concerned about dementia? We reached out to experts who explained everything. 'HSV-1 is a common virus to which almost everyone is exposed early in life,' says David Hunter, M.D., an assistant professor and neurologist with UTHealth Houston. 'It is best known for causing cold sores and is closely related to chicken pox and mononucleosis.' What these viruses have in common is that they are neurotropic, meaning they linger in the nervous system long after the initial illness, explains Linda Yancey, M.D., an infectious disease doctor at Memorial Hermann Health System, and can be reactivated by stress or lowered immunity. That's how, for instance, chicken pox can manifest later in life as shingles, adds Dr. Hunter. The virus's ability to infiltrate the nerves is believed to get it past the blood-brain barrier, a membrane that shields the organ from infection via the bloodstream. Thanks to that entry point, Dr. Hunter says, HSV-1 is the most common cause of viral brain inflammation in the United States. 'There is no vaccine for HSV and almost everyone will get it by adulthood,' Dr. Hunter adds. Cold sores are a mild case of it, and symptoms can be treated with antiviral drugs. Dormant HSV-1 may be reactivated by illness and reach the brain, explains Mark Santos, Ph.D., an assistant professor of microbiology and immunology at Touro University Nevada. This can trigger brain inflammation over time, known as herpes encephalitis,and in people with genetic risk factors, like the ApoE-4 gene, contribute to Alzheimer's development, he adds. 'We don't entirely know why ApoE-4 is a risk factor for Alzheimer's,' adds Dr. Hunter. 'The link to HSV could be that ApoE-4 impacts the blood-brain barrier and makes it easier for HSV to enter.' And the inflammation caused by that entry may heighten Alzheimer's risk. 'It is now universally accepted that inflammation in the brain is a key step in the development of Alzheimer's,' Dr. Hunter reiterates. In the three decades since the original study, doctors and researchers have learned much more about Alzheimer's disease and its connection to viral inflammation. For instance, several studies have found that being immunized for any disease (like COVID-19 or the flu) reduces Alzheimer's risk, says Dr. Hunter. 'Several other studies have shown that reducing inflammation in the brain helps prevent Alzheimer's,' he adds. Santos concurs. 'Since 1996, additional studies have found HSV-1 DNA in the brains of individuals with Alzheimer's. Lab studies have also shown that HSV-1 infection can trigger the buildup of amyloid-beta and tau—proteins strongly associated with Alzheimer's pathology,' he explains. However, there are a few disclaimers to note. Firstly, the posed risk is associated with people who contract HSV-1 in early life, giving it time to progressively cause inflammation. The risk may be lower in adults, says Santos. 'That said, if someone has other risk factors (like a weakened immune system or APOE-e4), adult-onset HSV-1 could still have long-term consequences,' he adds. Still, neurotropic viruses are extremely common, Dr. Yancey reiterates. 'This makes it difficult to tease out whether they are causing neurologic problems or are simply common in the general population, including people with neurologic problems,' she adds. In other words, because most people end up with HSV-1 doesn't necessarily mean that most people will get Alzheimer's. 'Most cold sores aren't a cause for concern,' Santos adds. 'They're common and usually well-controlled by the immune system. But for people with frequent outbreaks, weakened immunity, or APOE-e4, it may be worth discussing with a healthcare provider. The concern is not a single cold sore, but long-term viral activity in the brain.' More research, including long-term studies, is needed to make any solid associations, Santos and Dr. Yancey conclude. 'The current data is based on population-level surveys. There is no way to predict on an individual patient's level whether this has a meaningful impact,' says Dr. Yancey. Future research will, hopefully, at least help experts understand how antiviral treatment affects Alzheimer's risk, as well as identify better ways to detect when HSV-1 is active in the brain. 'The hope is that understanding how infections contribute to Alzheimer's will open up new ways to prevent or treat it—especially before symptoms start,' says Santos. Being vaccinated, exercising, engaging in mental stimulation, and maintaining a heart-healthy diet are all known ways to lower dementia risk, our experts say. Avoiding smoking or nicotine use of any kind can also 'drastically' reduce the risk, says Dr. Yancey. All of these habits and choices work together to support both immune and brain health. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50

Nigerian Medical Advocates Rally on Capitol Hill for J-1 Visa Fix and Immigrant Physician Bill
Nigerian Medical Advocates Rally on Capitol Hill for J-1 Visa Fix and Immigrant Physician Bill

Yahoo

time7 hours ago

  • Yahoo

Nigerian Medical Advocates Rally on Capitol Hill for J-1 Visa Fix and Immigrant Physician Bill

WASHINGTON, June 9, 2025 /PRNewswire/ -- The Nigerian Physician Advocacy Group (NPAG), will host a two-day Advocacy & Lobby Day on June 10–11, 2025, on Capitol Hill to highlight the vital role Nigerian American physicians play in filling healthcare shortages and call on Congress to remove systemic barriers to their continued service by reforming the J-1 visa program and passing the Conrad State 30 and Physician Access Reauthorization Act (H.R. 1201), also known as the "Doctors in Our Borders" bill. The NPAG delegation will be led by Dr. Susan Edionwe, Nigerian American physicians, health advocates, and community leaders. This initiative comes amid targets on international students at U.S. universities and growing concerns over the increasing number of J-1 visa denials, which prevent qualified international medical graduates (IMGs)—especially Nigerian-trained physicians—from contributing their expertise to underserved and rural communities across the United States. Nigerian American physicians have played an important role in filling healthcare shortages in the United States and the advancement of our country's healthcare system is dependent on the removal of systemic barriers to their continued service. "Doctors from Nigeria and across Africa have long served in America's most vulnerable communities—from inner cities to remote rural counties," said Dr. Susan Edionwe. "Fixing the J-1 process and passing H.R. 1201 is essential to ensuring our communities have access to the care they desperately need." "NPAG encourages policymakers, allies, and the media to recognize the indispensable contribution of Nigerian and African-trained doctors to the American healthcare system—and to take legislative action to protect and expand their role in advancing national health equity," said Dr. Susan Edionwe. About Conrad State 30 and Physician Access Reauthorization Act (H.R. 1201): H.R. 1201 a bipartisan bill, would reauthorize and expand the Conrad 30 waiver program, which allows J-1 physicians to remain in the U.S. after residency by serving in Health Professional Shortage Areas (HPSAs). The legislation provides states with greater flexibility, increases waiver caps, and reduces processing delays—ensuring medically underserved communities continue receiving essential care. About NPAG: The Nigerian Physician Advocacy Group is a national coalition of Nigerian American doctors and advocates committed to advancing health equity, shaping inclusive immigration policy, and addressing physician workforce challenges in the United States. View original content to download multimedia: SOURCE Nigerian Physician Advocacy Group (NPAG)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store